Nelson Chavarria
Cardiovascular Disease · New York, NYNPI 1962665679
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 219 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,488 and has fallen 88.9% since, to $276 in 2025.
Across 219 payments — averaging $45.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Boehringer Ingelheim$1K
- Cardiovascular Systems Inc.$900
- Medtronic$776
- Novartis$603
- Amgen$599
- plus $5K from 29 others
What the payments were for
- Food & beverage$9,892100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 12 | $1,285 |
| Boehringer Ingelheim | 19 | $1,001 |
| Cardiovascular Systems Inc. | 31 | $900 |
| Medtronic | 6 | $776 |
| Novartis | 20 | $603 |
| Amgen | 19 | $599 |
| Philips North America LLC | 6 | $559 |
| Boston Scientific | 7 | $488 |
| Biohaven Pharmaceuticals, Inc. | 5 | $406 |
| Johnson & Johnson | 17 | $339 |
| Bayer | 11 | $315 |
| Abiomed | 2 | $260 |
| Esperion Therapeutics, Inc. | 6 | $251 |
| AstraZeneca | 8 | $235 |
| Angiodynamics, Inc. | 1 | $195 |
| Amarin Pharma, Inc. | 3 | $183 |
| E.r. Squibb & Sons, L.L.C. | 10 | $179 |
| Penumbra, Inc. | 2 | $167 |
| Cvrx, Inc. | 1 | $150 |
| Janssen Scientific Affairs, LLC | 1 | $122 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $122 |
| Merck | 5 | $117 |
| Cook Medical LLC | 1 | $111 |
| Pfizer | 5 | $99 |
| Assertio Therapeutics, Inc. | 5 | $94 |
| EMD Serono, Inc. | 4 | $71 |
| Terumo Medical Corporation | 1 | $66 |
| Scpharmaceuticals Inc. | 3 | $53 |
| Avanir Pharmaceuticals, Inc. | 1 | $28 |
| Novo Nordisk | 1 | $25 |
| AbbVie | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Bristol Myers Squibb | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$723
- Xience Sierra Coronary Stent$497
- NURTEC ODT$487
- INFINITY$454
- Coronary Orbital Atherectomy System$383
- Resolute$375
- Impella$260
- Repatha$242
- ENTRESTO$231
- AlphaVac$195
- Launcher$170
- NEXLIZET$150
- NEXLETOL$150
- Barostim Neo System$150
- Optis Coronary Imaging System$146
- Indigo System$144
- Turbo Elite$142
- Vascepa$141
- ROTAPRO$138
- (4066) Tack Endo Sys ATK$125
How this compares
$9,892 in reported general payments places this provider in the 80th percentile of 2,302 cardiovascular disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 524 | $541,067 |
| EliquisApixaban | 305 | $296,704 |
| XareltoRivaroxaban | 134 | $117,550 |
| JardianceEmpagliflozin | 60 | $56,646 |
| JanumetSitagliptin Phos/Metformin Hcl | 58 | $48,592 |
| JanuviaSitagliptin Phosphate | 50 | $43,401 |
| BrilintaTicagrelor | 30 | $29,800 |
| OzempicSemaglutide | 27 | $25,150 |
| TrulicityDulaglutide | 14 | $19,749 |
| FarxigaDapagliflozin Propanediol | 14 | $13,915 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 249 | $8,136 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,759 |
| Valsartan | 310 | $7,718 |
| Metoprolol Succinate | 453 | $5,799 |
| Atorvastatin Calcium | 509 | $5,772 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $603 | $541,067524 claims |
| PfizerEliquis | $99 | $296,704305 claims |
| Johnson & JohnsonXarelto | $339 | $117,550134 claims |
| MerckJanumet, Januvia | $117 | $91,993108 claims |
| Boehringer IngelheimJardiance | $1,001 | $56,64660 claims |
| AstraZenecaBrilinta, Farxiga | $235 | $43,71544 claims |
| Novo NordiskOzempic | $25 | $25,15027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in New York
- Roger HajjarNew York$5.2M
- Gregg StoneNew York$2M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Megha PrasadNew York$813K
- Eyal HerzogNew York$645K
- Nisha JhalaniNew York$443K
- Roxana MehranNew York$432K
- Howard WeintraubNew York$328K
- Anuradha Lala-TrindadeNew York$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.